We aimed to assess the anti-biofilm activity of vancomycin, maltodextrin, and their combination against vancomycin resistant Staphylococcus aureus (VRSA) and vancomycin-susceptible S. aureus (VSSA) strains based on an in vitro static model. Biofilms of 4 VSSA and 2 VRSA strains were grown in a 96-well static model. Vancomycin 2 mM, maltodextrin 10 mM, and both in combination were tested using tetrazolium salt (XTT), resazurin, and cfu/well counts. The efficacy of the antimicrobial solutions was expressed as the percentage reduction in metabolic activity with each method. Overall percentage reduction in the metabolic activity of VSSA was 79.3%, 34%, and 75.7% for vancomycin, maltodextrin, and their combination (p<0.001). Overall percentage reduction in metabolic activity of VRSA was 46.7%, 27.8%, and 34.6% for vancomycin, maltodextrin, and their combination (p>0.05). Maltodextrin did not improve the anti-biofilm efficacy of vancomycin in VSSA or in VRSA biofilms. XTT cannot replace cfu counts as a means of quantifying cell viability. Futures studies are needed to assess the synergistic effects of other non-antimicrobial molecules combined with vancomycin.
ABSTRACT
We aimed to assess the anti-biofilm activity of vancomycin, maltodextrin, and their combination against vancomycin resistant Staphylococcus aureus (VRSA) and vancomycin-susceptible S. aureus (VSSA) strains based on an in vitro static model. Biofilms of 4 VSSA and 2 VRSA strains were grown in a 96-well static model. Vancomycin 2 mM, maltodextrin 10 mM, and both in combination were tested using tetrazolium salt (XTT), resazurin, and cfu/well counts. The efficacy of the antimicrobial solutions was expressed as the percentage reduction in metabolic activity with each method. Overall percentage reduction in the metabolic activity of VSSA was 79.3%, 34%, and 75.7% for vancomycin, maltodextrin, and their combination (p<0.001). Overall percentage reduction in metabolic activity of VRSA was 46.7%, 27.8%, and 34.6% for vancomycin, maltodextrin, and their combination (p>0.05). Maltodextrin did not improve the anti-biofilm efficacy of vancomycin in VSSA or in VRSA biofilms. XTT cannot replace cfu counts as a means of quantifying cell viability. Futures studies are needed to assess the synergistic effects of other non-antimicrobial molecules combined with vancomycin.
INTRODUCTION
Catheter-related bloodstream infection (C-RBSI) is a major cause of morbidity and mortality, which can increase to 25% in critically ill patients. C-RBSI increases the length of hospital stay and health care costs (1, 2). C-RBSI is caused by catheter colonization of extraluminal or endoluminal routes during insertion or maintenance (3) . Colonization results from the ability of microorganisms to form biofilm. The agents responsible for C-RBSI are as follows: gram-positive cocci, 70% (coagulase-negative staphylococci (4), Staphylococcus aureus, enterococci); gram-negative bacilli, 20% (Escherichia coli, Klebsiella pneumoniae); and yeast, 10% (Candida spp.) (5, 6) .
Guidelines recommend catheter withdrawal when a C-RBSI episode is suspected, particularly when it is caused by S. aureus or Candida spp. (7, 8) . However, catheter salvage is necessary in specific situations, such as absence of an alternative venous access, bleeding disorders, and specific patient conditions (9). In these situations, the main approach to an episode of C-RBSI involves the combination of systemic antimicrobial treatment with antibiotic lock therapy (ALT) (10) .
Guidelines recommend vancomycin, a first-generation glycopeptide, as the main choice of treatment for staphylococcal infections (coagu-lase-negative staphylococcus (4) or S. aureus infections) (11, 12) . However, several studies demonstratded that the anti-biofilm activity of vancomycin was not as effective as that of other antibiotics used for multidrug-resistant staphylococci (9, (13) (14) (15) . Widerspread prescription of vancomycin has led vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus (VRSA) to become increasingly common throughout the world, resulting in frequent treatment failures (16) (17) (18) .
In their flow biofilm-forming model, Kiamco et al. recently demonstrated that the addition of maltodextrin, a common polysaccharide sweetener, can enhance vancomycin activity by acting as a hyperosmotic agent, particularly in VRSA biofilm. Maltodextrin showed synergistic activity that enabled it to be used in the treatment of wound infections (19) . Although VRSA will represent a global health challenge in the future, no more than 20 strains have been described worldwide (16, 20, 21) . Thus, the combination of vancomyncin with agents encouraging antibiotic efficacy should also target vancomycin-susceptible S. aureus (VSSA). Moreover, no data have been reported on the possible role of the combination of vancomycin and maltodextrin in ALT solutions.
As for available diagnostic methods to test the in vitro metabolic activity of S. aureus biofilms, we recently reported a poor correlation between tetrazolium salt (XTT) and resazurin (22) . However, to the best of our knowledge, the comparison of these options in susceptibility assays and their correlation with cell viability tests, such as evaluation of colony-forming unit (cfu) counts, have only been assessed for yeasts and not for bacteria (23, 24) . Therefore, the aims of our study were to assess the anti-biofilm activity of the combination of vancomycin with maltodextrin against VSSA and VRSA strains as possible ALT and to evaluate the correlation between the 3 different diagnostic methods.
MATERIALS AND METHODS
The study was performed in the laboratory of the Department of Clinical Microbiology and Infectious Diseases at Gregorio Marañón Hospital, Madrid, Spain.
We designed a static in vitro 96-well plate model using clinical strains of S. aureus (4 VSSA and 2 VRSA). The VRSA strains were provided by Haluk Beyenal and Cesar A. Arias.
Vancomycin minimal inhibitory concentration value for VRSA-1, VRSA-2, and VSSA strains (mean) was, respectively: >32 mg/L, 5.8 mg/L, and 1.25 mg/L. The design was based on a 24-hour biofilm that was treated with various solutions and the results were extrapolated to the clinical setting of C-RBSI treatment with ALT.
Biofilm formation
Biofilm was formed as described by Peeters et al., with some modifications (25) . Briefly, a loopful of 24-hour fresh culture of each strain was inoculated in 20 ml of Tryptic Soy Broth (TSB) and incubated at 37°C in an orbital shaker for 24 hours. Inoculums were then washed in 3 centrifuge-resuspension cycles with phosphate-buffered saline (PBS), and pellets were reasuspended in 10 ml of TSB. These suspensions were adjusted to 0.5 McFarland turbidity (10 8 cfu/ml) using a turbidimeter and 100 µl was inoculated onto a 96-well plate. After 24 hours of biofilm formation at 37°C, plates were washed 3 times with PBS and treatment was administered. Each strain was tested in triplicate with a positive control and with TSB as a negative control.
Vancomycin and maltodextrin solutions and treatment procedure
Vancomycin (Sigma-Aldrich Química, S.L.), maltodextrin (Sigma-Aldrich Química, S.L.), and vancomycin-maltodextrin solutions were prepared in 3% TSB in concentrations of 2 mM, 10 mM, and 2 mM-10 mM, respectively, according to the concentrations used on the paper published by Kiamco et al (19) . After preparation, each solution was filtered using a 0.22-µm Millipore® filter. Solutions were prepared immediately before each experiment.
One hundred microliters of each solution was added to the completely dry plates, which were incubated at 37°C for 24 hours. The plates were then washed a further 3 times with PBS and dried at room temperature before the viability assays.
Quantification of metabolic activity by XTT assay
One hundred microliters of XTT (SigmaAldrich Química, S.L.)/menadione (0.5 mg/ml and 1.72 mg/ml) mixed at 10 ml/1 µl was inoculated in each well in darkness. The plate was then incubated at 37°C for 3 hours. Absorbance was measured at 492 nm in a spectrophotometer (Biochrom EZ Read 400), and the percentage of metabolic reduction was calculated according to equation 1.
Equation 1

Quantification of metabolic activity by resazurin assay
One hundred microliters of TSB 30 mg/ml and 30 µl of resazurin (Sigma-Aldrich Química, S.L.) 5 ng/ µl was added to each well of the plate in darkness and incubated at 37°C for 2 hours. Absorbance was then measured using a dual-wavelength model (570 nm measurement wavelength and 590 nm reference wavelength) in a spectrophotometer (Biochrom EZ Read 400). The percentage of metabolic reduction was calculated using equation 2.
Equation 2
where (εOX) λ2 is the molar extinction coefficient at 590 nm of the oxidized form, (εOX) λ1 is the molar extinction coefficient at 570 nm of the oxidized form, A λ1 and A λ2 are the absorbances of treated wells at 570 nm and 590 nm, respectively, and A°λ 1 and A°λ 2 are the absorbances of positive control at 570 nm and 590 nm, respectively.
Quantification of cfu per well
The wells were vigorously scraped in 100 µl of PBS, and the triplicates of each treatment and controls were mixed separately in a pool. Four 1:100 serial dilutions were performed, and 100 µl of each dilution was streaked on blood agar plates and incubated at 37°C for 24 hours. Colonies were countned, and the reduction in log 10 cfu/well was calculated using equation 3.
Equation 3
Statistical analysis
The qualitative variables are expressed with their frequency distribution. The quantitative variables are summarized as the mean (SD). Continuous variables were compared using the t test; nonnormally distributed variables were compared using the Kruskal-Wallis test. The differences between the groups were compared using the ANOVA test with a post-hoc comparison test by Games-Howell. All statistical tests were 2-tailed. 
RESULTS
The overall mean (SD) percentage reduction in metabolic activity and mean cfu in all strains when the 3 methods were assessed for vancomycin, maltodextrin, or both were, respectively, 68.4% (17.3%), 31.9% (20.5%), and 62.0% (25.0%) (p<0.05). Data regarding the overall percentage reduction for each method are shown in Table 1 . Using the XTT assay, the mean (SD) percentage reduction in metabolic activity for vancomycin, maltodextrin, and both were 65.9% (32.7%), 33.1% (26.3%), and 53.4% (35.1%) (p=0.041), respectively. With the resazurin assay, the mean (SD) percentage reduction in metabolic activity was 62% (22.3%), 21% (8.3%), and 59.3% (21.7%) XTT, tetrazolium salt; RZ, resazurin; cfu, colony-forming unit; V, vancomycin; M, maltodextrin; V+M, vancomycin + maltodextrin. 1 Statistically significant differences were found between V and V+M compared with M alone. V and V+M were efficient against S. aureus biofilm using all 3 methods.
(p=0.003) for vancomycin, maltodextrin, and both. The mean (SD) percentage reduction in cfu counts for vancomycin, maltodextrin, and both was, respectively, 77.4% (20.8%), 41.5% (22.0%), and 73.3% (23.9%) (p<0.001).
For VSSA strains, the overall mean (SD) percentage reduction in metabolic activity and cfu for vancomycin and the combination of vancomycin with maltodextrin was statistically significant compared with that of maltodextrin alone: 79.3% (9.0%) and 75.7% (15.6%) vs. 34.0% (9.3%), p<0.05 (Figure 1 ). In contrast, in VRSA strains, the overall mean (SD) percentage reduction in metabolic activity and cfu counts was not statistically significant between the groups: vancomycin, 46.7% (28.9%); maltodextrin, 27.8% (16.2%); and both, 34.6% (18.9%); p>0.05. Figure 2 . shows the percentage reduction for each therapy by the 3 different diagnostic methods for VSSA (2a) and VRSA (2b). No differences were found between vancomycin and its combination with maltodextrin in VSSA (p>0.05), although it was more active than maltodextrin alone (p<0.001). In VRSA, vancomycin led to a greater reduction in metabolic activity and cfu counts than the other therapies, although the differences were not statistically significant (p>0.05).
When we compared the correlation between the 3 methods used, no statistically significant correlation was found between any of the methods, either with the Bland-Altman graphs or ICCs (Figure 3) . The ICC for the combinations was as follows: cfu vs. XTT, 0.53; cfu vs. resazurin, 0.69; and XTT vs. resazurin, 0.63, ie, a moderate correlation between the 3 techniques.
DISCUSSION
Our static in vitro biofilm model did not enable us to demonstrate that the combination of maltodextrin with vancomycin had a synergistic effect against VSSA and VRSA strains. Percentage reduction in metabolic activity (by XTT or resazurin) and cfu counts for VSSA (A) and VRSA (B) strains treated with vancomycin, maltodextrin, and their combination. A. In VSSA, vancomycin alone and in combination with maltodextrin showed statistically significantly greater reduction in metabolic activity and cfu counts than maltodextrin alone (p<0.001). B. In VRSA, the only statistically significant difference was found between maltodextrin and the combination of both using the resazurin assay (p=0.012). © 1996-2018 C-RSBI is a major complication in hospitals, particularly in intensive care units (3, 27) . S. aureus C-RBSI is an issue of concern because it frequently causes long-term hospitalization, morbidity, and mortality (28) . A relationship was recently reported bertween high minimal inhibitory concentrations (MICs) for vancomycin (MICs ≥ 1.5 µg/ml) and poor clinical outcome in patients with S. aureus C-RBSI (29, 30) . Moreover, the anti-biofilm activity of vancomycin compared with other antibiotics in the clinical setting is also under discussion, and the use of the drug for ALT remains controversial (31) . Thus, our purpose was to analyze whether the combination of vancomycin with a hyperosmotic agent increased its activity against S. aureus biofilm sufficiently to be used in ALT.
Kiamco et al. described a synergistic effect of 10 mM maltodextrin combined with 2 mM vancomycin against S. aureus biofilm, with a significant reduction in volumetric biofilm coverage and average diffusion distance. The authors also observed changes in biofilm morphology and in oxygen penetration, concluding that the combination of vancomycin and maltodextrin increased the efficiency of biofilm treatment in wound infections (19) . In contrast, we found no statistically significant differences for the efficacy of vancomycin, whether alone or combined with maltodextrin, in reducing metabolic activity and cfu counts in VSSA or in VRSA biofilms. Although we used the same concentrations as Kiamco et al., the diagnostic methods for each study were different (19) . While we used a static plate model and cell viability assays to analyze viability and metabolic reduction, Kiamco et al. used a single-pass flat plate flow reactor to assess biofilm structure, oxygen penetration, antibiotic diffusion, and cell viability. Thus, vancomycin combined with maltodextrin altered various biofilm properties but did not increase vancomycin activity when metabolic activity was being measured. We found that in VSSA, the reduction in viability measured as cfu counts was approximately 80-90% for vancomycin and for the combination of vancomycin and maltodextrin.
These findings correlated with the results of Kiamco et al. and indicate that both therapies are effective but that the combination of vancomycin and maltodextrin was not synergistic. In contrast, in VRSA, none of the therapies enabled a reduction greater than 52% with any of the diagnostic methods used or even showed less activity when both were combined.
Moreover, the antimicrobial susceptibility profile and the level of biofilm production can affect the efficacy of an antimicrobial treatment. A possible explanation of the differences we observed with respect to Kiamco's study in the efficacy of the combined activity of vancomycin+maltodextrin could be related to a specie-specific background. In particular, a high level of biofilm production is key in the process of the bacte- rial tolerance. Is it possible that the absence of a statistical significance observed in our VRSA could be related to a different level of biofilm production between our strains and the one analyzed in Kiamco et al.
As resazurin is cheaper, less time-consuming, less toxic than XTT, and less laborious than cfu counts and the XTT assay is less time-consuming, provides faster results, and is less laborious than cfu counts, we aimed to find a correlation that could substitute cfu counts with any of the metabolic activity assays. However, as reported for yeasts (25, (32) (33) (34) , we were unable to establish a correlation between cfu counts, XTT, and resazurin using either Bland-Altman plots or ICCs in bacteria.
Nevertheless, considering a ± 10% reduction in the difference between methods as a good correlaotion, the correlation we obtained between the methods was moderate, suggesting that, depending on the researcher's goals, some methods are more suitable than others. However, results must be interpreted with caution.
In conclusion, based on our results in a static in vitro model, we could not demonstrate that maltodextrin improved the activity of vancomycin against S. aureus biofilm in ALT. As for diagnostic methods, neither XTT nor resazurin can replace cfu counts for the evaluation of anti-biofilm activity, as they measure different properties (metabolic activity and cell viability, respectively). Future studies are needed to find other synergistic agents to increase vancomycin anti-biofilm activity and thus optimize the conservative treatment of C-RBSI by ALT.
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